Clinical Trials Sponsored by Clinident Institute

Total 74283 results

Centre Leon Berard
Clinident Institute

Unknown

Evaluation of the Oncoral® Test in Epidermoid Carcinomas of the Upper Aerodigestive Tract

Carcinoma

France
AstraZeneca
Clinigen, Inc.

No longer available

Anifrolumab Early Access Program (AMANA)

Systemic Lupus Erythematosus
Clinigen, Inc.
Prometheus Laboratories

Terminated

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma (PROCLIVITY01)

Metastatic Melanoma

United States
Immunocore Ltd
Clinigen, Inc.

Available

A Cohort IND Expanded Access Program for Supporting Patient Access to Tebentafusp (Non Applicable)

Uveal Melanoma
Mirum Pharmaceuticals, Inc.
Clinigen, Inc.

Approved for marketing

A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)

Alagille Syndrome

United States
MorphoSys AG
Clinigen Healthcare Ltd

Approved for marketing

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

DLBCL
HealOr
Cato Research; Clinigene International Ltd

Unknown

Safety and Efficacy of HO/03/03 10μg in the Treatment of Plantar Neuropathic Diabetic Foot Ulcers (Truheal)

Diabetic Foot Ulcer

United States, India
H. Lee Moffitt Cancer Center and Research Institute
Clinigen, Inc.

Recruiting

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Melanoma Stage IV | Melanoma Stage III | Inoperable Disease

United States
Clinigen, Inc.
Johns Hopkins University; M.D. Anderson Cancer Center

Terminated

HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma (PROCLIVITY02)

Metastatic Melanoma

United States
Teikoku Seiyaku Co., Ltd.
ClinSearch; Clinigen, Inc.; CRM Biometrics GmbH

Completed

Efficacy and Safety of Esflurbiprofen Hydrogel Patch in the Treatment of Local Acute Pain

Soft Tissue Injuries | Sprains | Contusions | Strains | Bruises

Germany
APR Applied Pharma Research s.a.
Cavendish Impact Foundation; Clinigen, Inc.; Nephron Pharmaceuticals, Inc.

No longer available

ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE) (SAMICARE)

Critical COVID-19 With Respiratory Failure

United States
Ascendis Pharma Bone Diseases A/S
Clinigen Healthcare Ltd

Available

Expanded Access Program of Palopegteriparatide in Patients With Hypoparathyroidism

Hypoparathyroidism
Roberto Pili
Syndax Pharmaceuticals; Clinigen, Inc.; Indiana University Melvin and Bren Simon...

Active, not recruiting

High Dose IL 2 and Entinostat in RCC

Renal Cell Carcinoma

United States
Teikoku Seiyaku Co., Ltd.
ClinSearch; CRM Biometrics GmbH; SocraTec R&D GmbH; SocraMetrics GmbH; Clinigen Clinical...

Completed

Open Label Trial to Evaluate the Adhesion of TK-254RX in Healthy Volunteers.

Healthy

Germany
Karolinska Institutet
The Swedish Institute

Recruiting

MIDWIZE - Strengthening Midwives

Midwifery

Uganda
Karolinska Institutet
Children's National Research Institute

Completed

Resistance Exercise Reduces the Expression of Inflammation and Fibrosis Associated Genes in Autoimmune Myositis Patients

Exercise | Myositis

Sweden
Institute of Rheumatology, Prague
Karolinska Institutet

Completed

Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM (Prometheus)

Dermatomyositis | Polymyositis

Czech Republic
Institut Curie
National Cancer Institute, France

Completed

ER-One: A Double-blind Trial of Erector Spinae Block (ESP) Versus Paravertebral Block (PVB) Before Breast Cancer Surgery (ER-One)

Breast Surgery

France
Institut Bergonié
National Cancer Institute, France

Completed

A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma (RADIOSARP)

Soft-tissue Sarcoma

France
Institut Curie

Completed

Blood Levels of Tumor Cells in Predicting Response in Patients Receiving First-Line Chemotherapy for Stage IV Breast Cancer

Breast Cancer

France
Institut Curie

Completed

Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma

Intraocular Melanoma
Jules Bordet Institute
AstraZeneca; Institut Curie

Active, not recruiting

Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay)

Luminal B

France, Belgium
The Netherlands Cancer Institute
Institut Curie

Terminated

Pre- Versus Postoperative Accelerated Partial Breast Irradiation (PAPBI-2)

Breast Cancer | Neoplasms, Breast | Cancer of the Breast

France, Netherlands, Portugal, Spain
Institut Bergonié
National Cancer Institute, France

Completed

Validation of a Screening Tool in Geriatric Oncology (ONCODAGE)

Lymphoma | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Lung Cancer | Prostate Cancer

France
Institut Bergonié

Completed

Effect of Advertisements on Treatment Compliance in Women With Breast Cancer

Breast Cancer
Institut Curie

Completed

Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter

France
Institut Bergonié

Completed

MRI in Evaluating Early Response to Chemotherapy in Women Receiving Chemotherapy for Infiltrating Breast Cancer

Breast Cancer

France
Institut Bergonié

Completed

Psychological and Social Factors That May Increase the Risk of Developing Chronic Pain After Surgery in Women With Breast Cancer

Pain | Breast Cancer | Psychosocial Effects of Cancer and Its Treatment
Institut Curie

Unknown

Study of Tumor and Blood Samples From Women With Breast Cancer

Breast Cancer

France
Institut Bergonié

Unknown

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Pancreatic Cancer

France
Institut Curie

Unknown

Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer

Breast Cancer | Metastatic Cancer

France
Institut Curie
National Cancer Institute, France

Recruiting

LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) (LOC-R01)

Lymphoma, Large B-Cell, Diffuse | Central Nervous System Neoplasms, Primary

France
Institut Bergonié
National Cancer Institute, France

Completed

Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial (FRAIL-06)

Lymphoma

France
Institut Bergonié
National Cancer Institute, France

Completed

Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer (HORGEN)

Breast Cancer

France
Institut Curie

Unknown

Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye

Intraocular Melanoma

France
Karolinska Institutet
Patient-Centered Outcomes Research Institute; Kaiser Foundation Research Institute

Active, not recruiting

COMparison Between All immunoTherapies for Multiple Sclerosis. (COMBAT-MS)

Relapsing-remitting Multiple Sclerosis

Sweden
Karolinska Institutet
Tata Institute of Social Sciences

Completed

Perioperative Mortality Rate in Indian Trauma Patients

Trauma
Ageless Regenerative Institute
Instituto de Medicina Regenerativa

Withdrawn

Adipose Derived Stem Cell Therapy for Autism

Autism

United States
Ageless Regenerative Institute
Instituto de Medicina Regenerativa

Withdrawn

Safety and Efficacy of Adipose Derived Stem Cells for Non-Ischemic Congestive Heart Failure

Non-Ischemic Congestive Heart Failure

Mexico
Karolinska Institutet
Tata Institute of Social Sciences

Completed

Unmet Need for Massive Transfusion in Indian Trauma Patients

Trauma
Karolinska Institutet
Linkoeping University; Oregon Research Institute

Completed

Swedish Body Project for Prevention of Eating Disorders (sBodyProject)

Eating Disorders

Sweden
Ageless Regenerative Institute
Instituto de Medicina Regenerativa

Withdrawn

Safety and Efficacy of Adipose Derived Stem Cells for Congestive Heart Failure

Ischemic Congestive Heart Failure

Mexico
Ageless Regenerative Institute
Instituto de Medicina Regenerativa

Withdrawn

Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction (Acute MI)

Acute Myocardial Infarction

United States
Ageless Regenerative Institute
Instituto de Medicina Regenerativa

Withdrawn

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients After Stroke

Stroke

Mexico
Instituto de Investigação em Imunologia
Butantan Institute

Unknown

Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)

Cancer. | Melanoma. | Ovarian Cancer. | Lung Cancer.

Brazil
Butantan Institute
InCor - Instituto do Coração - HCFMUSP.

Withdrawn

Clinical Trial to Assess Safety and Immunogenicity of a Synthetic Vaccine Against Streptococcus Pyogenes

Rheumatic Fever
Ageless Regenerative Institute
Instituto de Medicina Regenerativa

Withdrawn

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stem Cells in Patients With Frailty Syndrome

Frailty Syndrome

Mexico
Ageless Regenerative Institute
Instituto de Medicina Regenerativa

Withdrawn

Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Diffuse Lesions in the Brain

Brain Lesion (General)

Mexico
Ageless Regenerative Institute
Instituto de Medicina Regenerativa

Withdrawn

Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered in Patients With Renal Failure

Renal Failure

Mexico
Institut Paoli-Calmettes

Completed

Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Neoplasms

France

Clinical Trials Sponsored by Clinident Institute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations